Opus Genetics (IRD) Revenue (2010 - 2026)
Opus Genetics (IRD) posted quarterly Revenue of $2.2 million for Q1 2026, down 50.64% year-over-year from $4.4 million in Q1 2025, and down 44.19% quarter-over-quarter from $3.9 million in Q4 2025.
Opus Genetics (IRD) Revenue (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Revenue for 8 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue fell 50.64% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $12.0 million (down 12.22% YoY), while the FY2025 annual figure was $14.2 million, up 29.15% from the prior year.
- Revenue eased to $2.2 million in Q1 2026 per IRD's latest filing, from $3.9 million in the prior quarter.
- Across five years, Revenue topped out at $39.8 million in Q4 2022 and bottomed at $1.1 million in Q2 2024.
- Historically, Revenue has averaged $6.2 million across 5 years, with a median of $3.4 million in 2023.
- Annual changes were most pronounced in 2023 — Revenue sank 95.76% — and 2025, when it soared 159.17%.
- Opus Genetics' Revenue stood at $39.8 million in 2022, then tumbled by 95.76% to $1.7 million in 2023, then soared by 154.41% to $4.3 million in 2024, then retreated by 10.16% to $3.9 million in 2025, then plunged by 44.19% to $2.2 million in 2026.
- Business Quant data shows IRD's Revenue at $2.2 million in Q1 2026, $3.9 million in Q4 2025, and $3.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - | 755,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 755,000.00 |
| Mar 31, 2026 | 2.16 Mn |
| Dec 31, 2025 | 3.87 Mn |
| Sep 30, 2025 | 3.08 Mn |
| Jun 30, 2025 | 2.88 Mn |
| Mar 31, 2025 | 4.37 Mn |
| Dec 31, 2024 | 4.30 Mn |
| Sep 30, 2024 | 3.87 Mn |
| Jun 30, 2024 | 1.11 Mn |
| Mar 31, 2024 | 1.71 Mn |
| Dec 31, 2023 | 1.69 Mn |
| Sep 30, 2023 | 11.94 Mn |
| Jun 30, 2023 | 3.67 Mn |
| Mar 31, 2023 | 1.75 Mn |
| Dec 31, 2022 | 39.85 Mn |
| Sep 30, 2021 | 489,000.00 |
| Jun 30, 2021 | 100,000.00 |
| Mar 31, 2020 | 1.15 Mn |
| Jun 30, 2010 | 18,750.00 |